metsera glp 1 Metsera, a well-funded obesity drug startup, sees chance to challenge Lilly, Novo Metsera announces positive results in
Description
However, most included studies focused on individuals diagnosed with binge eating disorder (BED)
doi:10.1371/journal.pone.0053111 95
PLoS One (2018) 13:e0201073
As the adverse health outcomes associated with obesity become increasingly publicized, the provider perspective on the condition has shifted, and providers across all specialties feel progressively more interested in writing off-label prescriptions for diabetes GLP-1s to treat obesity 3
Common Side Effects The most common side effects are nausea, bloating, vomiting, diarrhea, constipation, and early fullness
